Robert Besthof Biography and Net Worth

Insider of NRx Pharmaceuticals

Mr. Bestof is a global biopharmaceutical executive with a 25+ year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty diseases area, including small as well as billion-dollar brands in Ophthalmology, Neuroscience, Pain, and Pulmonary Vascular Disease. His teams have played key roles in translating new science into investable commercial paths, reshaping markets, launching breakthrough products, and closing numerous licensing deals. Mr. Besthof has worked for Eli Lilly, Wyeth, and most recently Pfizer, as Vice President Commercial Development Neuroscience & Pain. Earlier in his career he worked for Deutsche Band and for various consulting firms. He holds a B.A. from Case Western Reserve University and a master’s in international management from the Thunderbird School of Global Management.

How do I contact Robert Besthof?: The corporate mailing address for Mr. Besthof and other NRx Pharmaceuticals executives is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. NRx Pharmaceuticals can also be reached via phone at (484) 254-6134 and via email at [email protected]. Learn More on Robert Besthof's contact information.
Has Robert Besthof been buying or selling shares of NRx Pharmaceuticals?: Robert Besthof has not been actively trading shares of NRx Pharmaceuticals over the course of the past ninety days. Most recently, Robert Besthof sold 400 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $1,176.00, for a transaction totalling $470,400.00. Learn More on Robert Besthof's trading history.
Who are NRx Pharmaceuticals' active insiders?: NRx Pharmaceuticals' insider roster includes Robert Besthof (Insider), and Alessandra Daigneault (General Counsel). Learn More on NRx Pharmaceuticals' active insiders.
Are insiders buying or selling shares of NRx Pharmaceuticals?: In the last year, NRx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $46,800.00. The most recent insider tranaction occured on December, 17th when Chairman Jonathan C Javitt bought 40,000 shares worth more than $46,800.00. Insiders at NRx Pharmaceuticals own 19.0% of the company. Learn More about insider trades at NRx Pharmaceuticals.
Information on this page was last updated on 12/17/2024.

Robert Besthof Insider Trading History at NRx Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/15/2021	Sell	400	$1,176.00	$470,400.00

Robert Besthof Buying and Selling Activity at NRx Pharmaceuticals

NRx Pharmaceuticals Company Overview

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Today's Range

Now: $2.44

$2.36

$2.51

50 Day Range

MA: $2.83

$2.03

$3.67

2 Week Range

Now: $2.44

$1.15

$6.01

Volume

356,150 shs

Average Volume

436,705 shs

Market Capitalization

$68.56 million

P/E Ratio

N/A

Dividend Yield